Pliant Therapeutics Stock News

SOUTH SAN FRANCISCO, Calif., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics

Pliant Therapeutics Inc (PLRX) shares closed today 11.1% higher than it did at the end of yesterday. The stock is currently down 12.7% year-to-date, down 57.0% over the past 12 months, and down 44.6% over the past five years. Today, the Dow Jones Industrial Average rose 0.5%, and the S&P 500 rose 0.9%. Trading Activity Shares traded as high as $14.18 and as low as $11.28 this week.Shares closed 70.2% below its 52-week high and 16.1% above its 52-week low.Trading volume this week was 122.6% higher than the 10-day average and 55.9% higher than the 30-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.2. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed above its Bollinger band, indicating it may be overbought. Market Comparative Performance The company's share price beats the S&P 500 Index today, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price beats the Dow Jones Industrial Average today, lags it on a 1-year basis, and lags it on a 5-year basis The company share price beats the performance of its peers in the Health Care industry sector today, lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by 279.2% The company's stock price performance over the past 12 months lags the peer average by 222.4% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

Pliant Therapeutics, Inc. (NASDAQ:PLRX) shares gapped up before the market opened on Friday . The stock had previously closed at $14.22, but opened at $15.57. Pliant Therapeutics shares last traded at $14.95, with a volume of 745 shares trading hands. PLRX has been the subject of a number of research reports. Zacks Investment Research cut []

Zacks Investment Research cut shares of Pliant Therapeutics (NASDAQ:PLRX) from a hold rating to a sell rating in a research report report published on Monday, Zacks.com reports. According to Zacks, Pliant Therapeutics Inc. is a clinical stage biopharmaceutical company. It is focused on discovering and developing novel therapies for the treatment of fibrosis. The companys []

Karuna Therapeutics (NASDAQ:KRTX) and Pliant Therapeutics (NASDAQ:PLRX) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, analyst recommendations and dividends. Earnings & Valuation This table compares Karuna Therapeutics and Pliant Therapeutics revenue, earnings per share and []

Karuna Therapeutics (NASDAQ:KRTX) and Pliant Therapeutics (NASDAQ:PLRX) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, risk, earnings, dividends, institutional ownership, profitability and analyst recommendations. Risk & Volatility Karuna Therapeutics has a beta of 1.75, indicating that its share price is []

State Street Corp raised its position in Pliant Therapeutics, Inc. (NASDAQ:PLRX) by 1.3% in the second quarter, HoldingsChannel reports. The fund owned 385,008 shares of the companys stock after purchasing an additional 4,759 shares during the quarter. State Street Corps holdings in Pliant Therapeutics were worth $11,211,000 as of its most recent SEC filing. Other []

Stock analysts at Royal Bank of Canada initiated coverage on shares of Pliant Therapeutics (NASDAQ:PLRX) in a report released on Tuesday, The Fly reports. The brokerage set an outperform rating on the stock. Other equities analysts have also recently issued research reports about the company. Zacks Investment Research cut Pliant Therapeutics from a buy rating []

SOUTH SAN FRANCISCO, Calif., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced that Bernard Coulie, M.D., Ph.D., Pliants President and Chief Executive Officer, along with members of Pliants senior management team, will participate in virtual fireside chats at the following investor conferences:

SOUTH SAN FRANCISCO, Calif., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics

Pliant Therapeutics, Inc. (NASDAQ:PLRX) Investment analysts at Piper Sandler dropped their FY2021 earnings per share (EPS) estimates for Pliant Therapeutics in a research note issued to investors on Tuesday, November 9th. Piper Sandler analyst Y. Rahimi now forecasts that the company will post earnings per share of ($2.67) for the year, down from their []

Pliant Therapeutics, Inc. (PLRX) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agre

SOUTH SAN FRANCISCO, Calif., Oct. 07, 2021 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics

A positive phase 2 clinical trial readout was a positive step in the right direction for this biotech start-up.

SOUTH SAN FRANCISCO, Calif., Sept. 03, 2021 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutic